Pharmaceuticals for contraception/hormone substitution containing a biogenous estrogen component

US5633242A · kind A · utility

Inventors

• Michael Oettel · Jena, DE
• Hermann Osterwald · Glückstadt, DE
• Claudia Moore · Jena, DE
• Thomas Gr aser · Erfurt, DE

Key dates

• Filing date: Aug 3, 1995
• Grant date: May 27, 1997
• Expiry date: Aug 3, 2015

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P15/18
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to a compound preparation for contraception and hormone replacement that consists of three steps totalling 28 daily doses. The pharmaceutical is characterized in that step 1 consists of 3 or 4 daily doses, each containing a preparation in which the active ingredient is at least one biogenous estrogen component, step 2 consists of 20 to 22 daily doses, each containing a preparation in which the active ingredients are at least one biogenous estrogen and one gestagen component from the group of C.sub.21 -gestagens including progesterone, as well as dienogest, desogestrel, 3-keto desogestrel, gestodene, levonorgestrel, norgestimate, norethisterone, norethisterone acetate and dydrogesterone, and step 3 consists of 3 or 4 daily doses, each containing a preparation in which the active ingredient is at least one biogenous estrogen component.